− DR − ), peripheral blood CD34 + cell (PBCD34 + ) count on first apheresis day, or various clinical factors were associated with low blood counts 6 months post ASCT. Thirty-four patients were excluded from analysis either because of death (n = 17) or reinduction chemotherapy prior to 6 months post ASCT (n = 13), or because of lack of follow-up data (n = 4). Of the remaining 136 patients, 46% had low WBC (Ͻ4 × 10 9 /l), 41% low platelets (Ͻ150 × 10 9 /l), and 34% low hemoglobin (Ͻ120 g/l) at a median of 6 months following ASCT. By Spearman's rank correlation, both the total CD34 + cell dose/kg and the PBCD34 + count correlated with 6 month blood counts better than any subset of CD34 + cells or any clinical factor. The PBCD34 + count was overall a stronger predictor of 6 month blood counts than was the total CD34 + cells/kg infused. Both factors retained their significance in multivariate analysis, controlling for clinical factors. In conclusion, subsets of CD34 + cells and clinical factors are inferior to the total CD34 + cell dose/kg and PBCD34 + count in predicting 6 month blood counts following ASCT. Bone Marrow Transplantation (2000) 26, 1299-1304.
eage commitment can be detected and enumerated using flow cytometric techniques. 7 These committed progenitor cells, expressing myeloid (CD33, CD13), 8 erythroid (CD71), 9 and megakaryocytic (CD41, CD61) 10 markers, have also shown some correlation with engraftment following ASCT.
1,2,4,11 However, controversy exists regarding the relative merit of using the dose of CD34
+ subsets for predicting the early reconstitutive capacity of autologous stem cell grafts. 1 There is considerably less information available about possible factors that affect long-term hematopoietic engraftment after ASCT. Lower numbers of CD34 + cells/kg have been reported to correlate with the presence of abnormal peripheral blood counts at both 6 and 12 months post ASCT. [12] [13] [14] [15] Patients receiving a larger cell dose may experience less fever and require fewer transfusions, antibiotics, and days in hospital in the first year after transplantation. 13 However more information is needed about the relative influence of CD34 + cell dose, CD34 + subsets, and clinical factors on long-term hematopoiesis.
In this retrospective study, we have evaluated the effect of CD34 + cell dose, peripheral blood CD34 + cell count, and CD34
+ subsets on long-term peripheral blood counts (WBC, hemoglobin, and platelets) 6 months following ASCT. In addition, we studied the influence of pretransplant clinical factors on these outcomes.
Materials and methods

Patients
One hundred and seventy consecutive patients underwent a single ASCT with unmanipulated autografts in Calgary between January 1997 and November 1999. Thirty-four patients were excluded from analysis either because of death (n = 17) or re-induction chemotherapy within 6 months of ASCT (n = 13), or because of lack of follow-up data (n = 4). Patients with evidence of relapsed or persistent disease after autografting were included if no systemic therapy was given before 6-month blood counts could be evaluated. The characteristics of the remaining 136 patients are listed in Table 1 . Nineteen patients (14%) had marrow involvement prior to mobilization.
A small group of four patients received hematopoietic growth factor-only mobilization with G-CSF daily for at least 3 days and apheresis starting on day 4. A second group , cisplatin 105 mg/m 2 (DICEP) divided over days 1-3 and G-CSF 300 g (Ͻ70 kg) or 480 g (Ͼ70 kg) s.c. starting on day 14, and were scheduled for apheresis on days 19, 20 or 21. The remaining 78 patients underwent mobilization with G-CSF and single agent or combination chemotherapy dosed to produce short-duration neutropenia and thrombocytopenia that would not require platelet transfusion. These 78 patients received daily G-CSF 300 g (Ͻ70 kg) or 480 g (Ͼ70 kg) s.c. starting on days 7 or 8, and underwent apheresis on days 13 or 14. The most common mobilization regimens for these patients were based upon cyclophosphamide 2 g/m 2 (n = 57), ifosfamide 4.5 g/m 2 , etoposide 400 mg/m 2 and cisplatin 100 mg/m 2 (n = 11), taxanes (n = 8) or high-dose Ara-C (n = 2). Blood stem cell apheresis and cryopreservation methods have been previously described. 16 Conditioning regimens for ASCT varied by diagnosis and study protocol. They were all considered to be myeloablative or profoundly myelosuppressive, requiring ASCT for timely blood count recovery. Lymphoma and multiple myeloma patients , n = 5) or thiotepa-based (n = 11). Total body irradiation was included in the conditioning regimen for 16% of patients, while 52% received post-transplant consolidation radiotherapy to areas of prior disease involvement. G-CSF at doses of 300 (Ͻ70 kg) or 480 (Ͼ70 kg) g/day s.c. was administered from day +7 post transplant until ANC Ͼ1.5. All patients provided written informed consent and all studies were approved by the institutional review board.
Blood stem cell enumeration
To ascertain the optimal timing for apheresis and ensure the best possible yield of stem cells, CD34
+ cell counts were measured in peripheral blood by flow cytometry daily from the fifth day of G-CSF until apheresis was complete. 
Statistics
Measures of long-term marrow engraftment were white blood cell count (WBC), hemoglobin (Hb), and platelet count obtained closest to six months post ASCT. All values were measured at least five months post transplant and ranged from 5 to 24 months (median 6.0 months). Low blood counts in Calgary are defined as WBC р4.0 × 10 9 /l, Hb р120 g/l and platelets р150 × 10 9 /l. A number of clinical factors that could potentially affect long-term engraftment were analyzed including age, gender, diagnosis, remission status, number of prior chemotherapy regimens, prior radiotherapy, morphological bone marrow involvement, mobilizing regimen, conditioning regimen, use of total body irradiation (TBI) in conditioning, relapse post ASCT, and post-ASCT consolidation radiotherapy.
In univariate analysis, Spearman's rank correlation test was used for continuous independent variables. KruskalWallis rank sum test was used for categorical independent variables. Logistic models were then built to study the effect of a predictor with other variables being simultaneously controlled. CD34
+ cell count was analyzed as the number of CD34 + cells/kg actually infused. The peripheral blood CD34
+ (PBCD34 + ) cell count analyzed was the count measured on the first apheresis day, regardless of how many apheresis procedures a patient underwent. [17] [18] [19] and CD34 + 41 + (megakaryocyte progenitors). Finally, logistic models were used to determine if the various clinical factors, CD34
+ cell dose/kg, CD34 + subsets, peripheral blood CD34
+ cell count and measures of early engraftment were independently associated with the long-term risk of having low peripheral blood counts after ASCT. The CD34 + cell dose/kg, PBCD34 + cell count, and CD34 + subsets were compared as continuous variables, however, cat-egorical ranges of the CD34 + cell dose/kg and PBCD34 + cell count were used in multivariate analysis.
Results
A median dose of 9.86 × 10 6 CD34 + cells/kg was infused (range 1.4-70.93). The entire collected product was infused in 107 patients, whereas only half (26 cases) or a third (three cases) of the product was given to 29 patients. The remaining product was stored for possible second transplant for the latter group. None of these 29 patients received the second ASCT before the study endpoint of the 6 month CBC. The median PBCD34
+ count on the first apheresis day was 156 × 10 6 /l (range 6-1783). A very good correlation was found between (log) PBCD34
+ cell count and (log) CD34
+ cell dose received (r = 0.86, P Ͻ 0.0001).
Engraftment
Rapid recovery of marrow function was seen for most patients after ASCT. Patients reached an absolute neutrophil count у0.5 × 10 9 /l after a median of 11 days (range 8-17 days). A platelet count у20 × 10 9 /l, unsupported by transfusion, was achieved after a median of 11 days (range 8-80 days). Eighty-eight percent were transfusion independent with platelet count у20 × 10 9 /l by day 14 and 98% by day 21. A platelet count у100 × 10 9 /l was achieved by a median of 15 days (range 10 to greater than 185 days), and in 90% by 30 days post ASCT. Five percent of patients never achieved a platelet count у100 × 10 9 /l. In addition, early platelet engraftment did not ensure normal long-term thrombopoiesis as 38% of those patients whose platelets recovered to у100 × 10 9 /l within 30 days of ASCT continued to have thrombocytopenia in the follow-up period, and in 13% the platelet count fell to Ͻ100 × 10 9 /l. Long-term engraftment data were available for all 136 patients. Relapse was observed in 15 of them, none of whom had received systemic therapy for relapse prior to being studied. Several months following ASCT, 46% of patients had low WBC, 41% low platelets and 34% low hemoglobin. Abnormalities of only a single lineage were seen in 32% of patients, 27% had low counts in two cell lines, and 11% were pancytopenic with low WBC, hemoglobin and platelets. Normal blood counts were seen in 30%. The median value for WBC was 4.1 × 10 9 /l (range 0.8-12.3), for hemoglobin was 124 g/l (range 76-160) and for platelets 159 × 10 9 /l (range 2-466). Poor engraftment of any one cell line several months after ASCT was significantly associated by univariate analysis with the presence of abnormalities in each of the other two cell lines (association between low WBC and low platelets, P Ͻ 0.0001, between low WBC and hemoglobin, P = 0.011, and between low platelets and low hemoglobin, P = 0.005).
Predictors of long-term engraftment by univariate analysis
By univariate analysis (Spearman's rank correlation, Table 2 ), all CD34
+ subsets studied correlated with low pla- + count and the total CD34 + cell dose/kg infused correlated well with successful long-term engraftment of WBC and platelets, and showed a stronger relationship than any individual subset of CD34
+ cells. Table 3 shows the percent of patients with low counts in the long-term after ASCT according to the total CD34 + cell dose received and PBCD34
+ count at first apheresis. For the purpose of this analysis, patients were grouped into quartiles based on the CD34 + cell dose × + cell dose/kg were predictive of engraftment several months after ASCT ( Table 3 ). The PBCD34
+ count was a better predictor of long-term WBC and red cell engraftment while the total CD34
+ cell dose/kg was marginally better for long-term platelet engraftment.
Several clinical factors had a significant effect on longterm blood counts by univariate analysis. A diagnosis of breast cancer (P = 0.0004), female sex (P = 0.0004), morphological marrow involvement by disease (P = 0.022), use of non-melphalan containing conditioning regimen (P = 0.002), and conditioning without TBI (P = 0.004) were all associated with a low WBC. Older age (у46) was associated with low hemoglobin (P = 0.003). Need for more than one apheresis procedure (P = 0.0009), TBI containing regimens (P = 0.018), and the number of prior chemotherapy regimens (P = 0.017) were associated with poor long-term platelet engraftment. The use of post-ASCT consolidation radiotherapy was not associated with long-term engraftment.
Predictors of long-term engraftment by multivariate analysis
Due to the strong correlation between the PBCD34 + count and the infused CD34 + dose/kg, linear models were set up for each of these two co-dependent variables separately to avoid multicolinearity. When multivariate analysis was applied in this way, and controlling for the various clinical factors, the PBCD34 + count and the total CD34 + cell dose/kg continued to predict for low WBC (P Ͻ 0.0001 and P Ͻ 0.0001, respectively) and platelets (P Ͻ 0.0001 and P = 0.0002, respectively). In addition, the PBCD34 + count predicted for anemia when studied in multivariate analysis as a categorical variable (P = 0.037). None of the clinical factors or CD34
+ cell subsets showed a consistent relationship with long-term trilineage engraftment by multivariate analysis.
Discussion
Few studies have addressed the issue of hematopoietic engraftment and marrow function beyond the immediate + cells on long-term engraftment and observed that lower cell doses also correlates with transfusion and antibiotic requirements, febrile episodes and days of hospitalization post ASCT.
In this study, we attempted to analyze factors that may influence long-term bone marrow function after ASCT. Less than one third of patients in our study had completely normal WBC, platelets and hemoglobin at a median of 6 months post ASCT. Our results confirm a strong association between CD34
+ cells/kg infused and long-term engraftment. The number of circulating CD34 + cells in the peripheral blood has been shown to predict the number of CD34 + cells that can be collected by apheresis. 20, 21 In this study, very good correlation was seen between the number of PBCD34 + cells as measured on the first apheresis day, and the total number of CD34 + cells/kg infused. The predictive strength of these two measures was very close, as may be expected from their close correlation with one another, and the differences did not reach statistical significance. The PBCD34 + cell count also correlated well with long-term engraftment by multivariate analysis, and seemed to be a better predictor of low WBC and Hb than was the infused CD34 + cell dose/kg. Patients with a PBCD34 + count above the median count of 150 × 10 9 /l, or CD34 + cell doses above the median of 10 × 10 6 /kg were most likely to have normal long-term peripheral blood counts ( Table 3 ). The intermediate and lowest ranges on the other hand frequently produced cytopenias, although it is worth noting that low counts were not infrequent even in patients whose PBCD34
+ count or CD34 + dose were above the upper quartile for the study population. Though both measures of CD34 + cell mobilization correlate with both early and late engraftment, rapid early hematopoietic recovery did not ensure normal long-term hematopoietic engraftment.
The predictive value of CD34 + cells/kg and the peripheral blood CD34 + cell count remained statistically significant even after controlling for other variables in multivariate analysis. None of the other factors studied had a consistent effect by multivariate analysis on long-term engraftment. As shown in Table 2, CD34 + cell subsets, could, in some cases, correlate with long-term engraftment by univariate analysis. However, both the CD34 + cells/kg and the PBCD34 + cell count correlated better than any of the CD34 + subsets. Only these two measures remained significant in multivariate analysis, with none of the subsets of cells continuing to be predictive.
Several limitations to this study must be recognized. We retrospectively studied a heterogeneous patient population that received a number of different mobilization and chemotherapy regimens. Although we did not identify a significant relationship of any clinical factor with long-term hematopoiesis in multivariate analysis, we cannot conclude that one does not exist. We may simply have had too few study subjects to detect such an association. Another limitation is that in 15 patients, the follow-up blood counts were performed after confirmed relapse of their primary malignancy. Although no systemic chemotherapy had been administered from the time of ASCT until the 6 month CBC, the CBC for these patients may have been affected by disease recurrence. However, the relationship of the 6 month CBC to CD34
+ dose or PBCD34 + count was independent of relapse (data not shown). Another problem was the variation in the timing of the follow-up CBC by the physicians following the patients after transfer back from the transplant unit. The majority of patients, however, did have a CBC measured between 5 and 7 months post ASCT.
The cut-off values we used for peripheral blood counts represent the lower limit of normal range in our laboratory. These endpoints were chosen to reflect what would best be described as normal hematopoiesis, so that patients with any evidence of abnormal hematopoiesis could be identified and analyzed. It could be argued that the use of lower values to define these endpoints may have had more clinical relevance. However, even mild anemia that would not ordinarily require transfusion can adversely affect the quality of life of cancer patients. Quality of life improves up to a hemoglobin of 120 g/l, making a normal hemoglobin an important long-term goal following cancer therapy. 22, 23 In addition, low blood counts may be associated with an increased replicative burden on existing stem cells, resulting in their rapid 'aging'. One can theorize that this proliferative stress may possibly result in higher incidences of clonal disorders later in life. Such a theory is supported by reports of telomere shortening in peripheral mononuclear cells of patients who had undergone ASCT, and negative correlations with the number of mononuclear cells infused. 24 Further, Friedberg and colleagues 25 have recently reported a negative correlation between the infused cell dose and incidence of myelodysplasia after autologous bone marrow transplantation.
The value of PBCD34 + cell count in predicting long-term hematopoietic outcome after ASCT has not previously been recognized. From our data, the PBCD34 + cell count seems to be at least as good as, or perhaps even a better predictor of long-term engraftment than the CD34 + dose/kg. This is particularly true considering that 21% of patients did not receive the entire collected product. The data were analyzed, however, based on the actual infused dose and not the collected dose. One might expect the infused dose to correlate better than the mobilized PBCD34 + count. The finding that the PBCD34 + count correlates better with longterm engraftment than the infused CD34 + dose may indicate that the PBCD34 + count is a marker of the quality of the + cells in extra apheresis procedures. Furthermore, there may be some effect of cryopreservation and thawing on the final infused product that would diminish the capacity of 'poor' quality products for long-term hematopoiesis more than superior products. Such variables would have no effect on the PBCD34 + cell count. We hypothesized that the quality of the autograft could be assessed by measuring subsets of CD34 + cells. Our study, however, demonstrated that none of the subsets analyzed were good surrogate markers of autograft quality. Long-term hematopoiesis may be dependent on a population of CD34-negative cells or some subset of CD34 + cells that we did not measure (ie true stem cells). 28, 29 If this is true, the PBCD34 + cell count may better reflect this unmeasured cell population than the total CD34 + cell dose infused.
In conclusion, our results suggest that the total CD34 /l) on the first apheresis morning is perhaps an even better predictor of long-term hematopoiesis than the infused CD34 + dose/kg. This in turn suggests that the PBCD34 + count is a marker for collecting a high quality autograft, and that the quality of the autograft is not adequately assessed by the CD34 + subsets we measured. Finally, it is reported that most patients who receive the currently accepted minimum CD34 + dose for autografting (2-5 × 10 6 CD34 + cells/kg) will have low blood counts at a median of 6 months post ASCT. Our study suggests that the risk of having prolonged low blood counts may not be minimized unless the CD34 + cell dose is Ͼ10 × 10 6 CD34 + cells/kg. This result needs to be confirmed by other investigators.
